# EDGAR Filing Document

**Accession Number:** 0001374690
**File Stem:** 0000899243-23-004434
**Filing Date:** 2023-2
**Character Count:** 7339
**Document Hash:** c2aff7864ac30641138786b575e70627
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-004434.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0000899243-23-004434

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230207

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shankar Gopi
- **CENTRAL INDEX KEY:** 0001965014

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36510
- **FILM NUMBER:** 23607111

**MAIL ADDRESS:**
- **STREET 1:** C/O LARIMAR THERAPEUTICS, INC.
- **STREET 2:** THREE BALA PLAZA EAST. SUITE 506
- **CITY:** BALA CYNWYD
- **STATE:** PA
- **ZIP:** 19004
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Larimar Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001374690
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 203857670
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** THREE BALA PLAZA EAST. SUITE 506
- **CITY:** BALA CYNWYD
- **STATE:** PA
- **ZIP:** 19004
- **BUSINESS PHONE:** 844-511-9056

**MAIL ADDRESS:**
- **STREET 1:** THREE BALA PLAZA EAST. SUITE 506
- **CITY:** BALA CYNWYD
- **STATE:** PA
- **ZIP:** 19004

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAFGEN, INC.
- **DATE OF NAME CHANGE:** 20100301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAFGEN INC
- **DATE OF NAME CHANGE:** 20060906

## Ex-24

```
<PRE>
                                                                      Exhibit 24
                           LIMITED POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints the Vice President of Regulatory Affairs and Counsel and Chief
Financial Officer of Larimar Therapeutics, Inc. (the "Company") with full power
to act singly, as the undersigned's true and lawful attorneys-in-fact, with full
power of substitution, to:

       (1)  execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director and/or beneficial owner of the Company,
Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange
Act of 1934, as amended, and the rules thereunder;

       (2)  do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4,
or 5, complete and execute any amendment or amendments thereto, and timely file
such form with the SEC and any stock exchange or similar authority; and

       (3)  take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney in fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

       The undersigned hereby grants to the attorneys-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact or such attorney-
in-fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.

       This power of attorney shall remain in full force and effect until
revoked by the undersigned in a signed writing delivered to the attorney-in-
fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 7th day of February, 2023.

                                            /s/ Gopi Shankar
                                            ----------------------------
                                            Signature

                                            Dr. Gopi Shankar
                                            ----------------------------
                                            Print Name

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shankar Gopi<br><sub>(Last) (First) (Middle)</sub><br>C/O LARIMAR THERAPEUTICS, INC.<br>THREE BALA PLAZA EAST, SUITE 506<br><sub>(Street)</sub><br>BALA CYNWYD, PA 19004<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Larimar Therapeutics, Inc. [ LRMR ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-02-07 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Development Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit List - Exhibit 24 - Power of Attorney

**Signature:** /s/ Jennifer Johansson, Attorney-in-fact  
**Date:** 2023-02-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**